BioStock: BioInvent focus on first line treatment

BioInvent’s phase I dose escalation study of BI-1206, combined with MSD’s pembrolizumab, showed promising clinical activity in heavily pre-treated patients with advanced solid tumors. With a phase IIa study planned for treatment-naive NSCLC and uveal melanoma patients in H2 2025, we contacted CMO Andres McAllister for comment.

Read the full interview at biostock.se:

https://biostock.se/en/2025/06/bioinvent-focus-on-first-line-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/